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SUMMARY.-The results of treating two series of patients with Burkitt's
lymphoma are presented in the form of survival curves. The second series
shows an improved survival rate which seems to be due to a potentiating effect
by potassium iodide on oral cyclophosphamide. So far no reason for this
effect has been found.
SINCE 1962 patients with Burkitt's lymphoma have been treated almost
exclusively here with oral cyclophosphamide. Three patients out of 48 so treated
have had parenteral administration of the drug initially. Latterly a few patients
who have developed central nervous system lesions have been given intrathecal
methotrexate. In 1967 a patient with Kaposi's sarcoma receiving potassium
iodide for a supposed mycosis improved dramatically when given cyclophos-
phamide. A potentiating effect was suspected and so a combination of cyclo-
phosphamide withpotassium iodide was used thereafter intreating cases of cancer
including 24 patients with Burkitt's lymphoma. The result of treating the first
10 of these has been reported (Williams, 1969).
8taging
Incomparing two series ofpatients theinterpretation ofresults canbe erroneous
if the proportions of different stages ofseverity of the condition vary in the two
series. A method ofstaging is therefore used for these series which endeavours to
classifypatientsby initial clinicalpresentation so that thestagesrepresent increas-
ingseverity andworseningprognosis. Byusingthisstaging incomparing survival
curves a more accurate assessment ofthe results of treatment can be made. As a
justification for the method the first figure shows the survival curves by stage for
all the 48 cases treated with cyclophosphamideplus one other treated in 1961 with
oral methotrexate. It can be seen that stages show levelling out ofthe curves at
71% for Stage A, 46% for Stage B, 22% for Stage C, and no levelling out for
Stage D. These stages are defined as follows:
A. Patients with tumours above the clavicular line without cranioneuropathy.
B. Patients with tumours below the clavicular line witli or without tumours
above the line without cranial or spinal neuropathies.
C. Patients with cranial or spinal neuropathies regardless of tumour sites and
those with tumours oflong bones or the vault ofthe skull, which sometimes
precede bone marrow involvement.
D. Patients with involvement of the central nervous system (malignant
pleocytosis of the cerebro-spinal fluid) or with bone marrow involvement,
orpatients who die in 2 weeks without any apparent response to treatment.38 E. R. WILLIAMS
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In this method of staging the neuropathies are given a place commensurate
with their adverse prognostic significance in these two series.
Survival curves
Fig. 2 shows the survival curves for all the Series I and 11 cases. Each series
is shown by two curves, one for all cases in the seri'es, and one for biopsy proven
cases only. The difference in the survival rates between biopsy proven and all
cases is small, suggesting that clinical diagnoses wereprobably true. Most ofthe
diagnoses made on clinical grounds only have been cheqked by Dr. Burkitt and
Professor Hutt as
" very probable
" after examination of the records and photo-
graphs ofthe patients. Thepatients in both series received 30-40 mg. perpound
of body weight of oral cyclophosphamide, 200 to 400 mg. daily, and those in
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FIG. l.-Survival curves to justify staging.
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RiG. 2.-Comparison of Series I and 11 survival curves.42 E. H. WILLIAMS
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FiG. 3.-Comparative survival curves for each stage.
Series 11 received in adclition 1200 to 1800 mg. per day ofpotassium iodide in a
mixture. The over-allimprovement in survival is fromapproximately20% in the
first series to 50% in the second. The improvement in results is shown more
clearly in Fig. 3 where the survivals are analysed by stage. In Stage A the
improvement is from 50% to 100%. In Stage B from 17% to 75%, and it should
be noted that the only death in Series II Stage B patients was No. 98 whose
regime of treatment was irregular. This patient's history is given in detail later.
The curve given for Series 11, Stage B has to be interpreted in the light of Case
No. 109. The untimely death of this patient after 68 weeks survival has exerted
adisproportionateeffect onthe curveforthetimebeing. Itwould appear thatthe
survival level is above that for Series 1, Stage B patients. The death of thisRESULTS OF TREATING BURKITT5S LYMPHOMA 43
patient has also reduced the over-all survival rate from approximately 60% to
50%inSeriesllpatients. CaseNo.109presentedwithjaw,tibial,andparaspinaI
tumours and was in totalparaplegia. Herespondedslowly but completely to one
course of cyclophosphamide and potassium iodide. Five months later he deve-
loped a small orbital tumour which responded immediately to a second course of
treatment. Three months after this he developed a Buruli ulcer of his buttock,
but was otherwise fit and well up to the time ofhis terminal illness. He was seen
3 weeks before he died, and apparently became suddenly ill and died within 2
weeks. He was not taken anywhere for treatment and the description given of
his illness does not permit of any definitive diagnosis. Case No. 43 in Series I
died after 58 weeks but she was ill for a long time with central nervous system
lesions. In Stage D the improvement in survival in Series 11 is minimal.
Special comment8
Comment should be made on the first threepatients treated in Series IL The
present regime for the administration ofpotassium iodide was then not properly
developed and so they are atypical.
Case, No. 92.-A boy of 8 whose first jaw tumour was treated with oral cyclo-
phosphamide only. When he relapsed 3 months later potassium iodide was
added to the course of treatment. He relapsed again after another 10 months
and was treated with the proper regime. He is the longest surviving patient in
this series at 155 weeks.
Ca8e No. 98.-A girl of 11 with ovarian tumours. She had potassium iodide
with the first course of treatment but not with the second and third. Her first
relapse was with an orbital tumour and third nerve palsy. She later developed
central nervous system lesions with malignant pleocytosis of the cerebro-spinal
fluid. She was treated with intrathecal methotrexate with only slight response.
The course ofher illness illustrates the progress from Stage B into C, andfinally D
with death at 30 weeks.
Ca8e No. 105.-This was a girl of 8 with a long history of 3 months and a
large jaw tumour and seventh cranial nerve palsy on admission. She was given
intravenous cyclophosphamide initially followed by the oral form of the drug
combined withpotassiumiodide, but the administration ofthe latter wasirregular.
She died at home at 8 weeks with what seemed to be central nervous lesions from
the description given.
DISCUSSION
Previous work on patients with Burkitt's lymphoma in the West Nile District
of Uganda has been largely confined to epidemiology, and the phenomenon of
CC space-time clustering
" has been noted (Pike et al., 1967; Williams et al., 1969).
The two series of patients described were treated in a small mission hospital
situated in a rural area and the consequent reduction in standards ofdiagnosis and
medical care is reflected in some cases notbeingbiopsied or otherwiseinvestigated.
Financial stringency accounts for the exclusive use of oral cyclophosphamide as
the main therapeutic agent, and this in itself may make the observations on
treating these two series more valuable. There is a special interest taken in this
hospital inpatients with cancer (Burkitt et al., 1969), but the reasonwhy so many
patients with Burkitt's lymphoma have been treated here rather than at a44 E. H. WILLIAMS
specialised centre has been that such a centre is 300 miles awayby bus. Patients
are often too ill to take a long bus journey and also parents, will often refuse to
take their child so far away from home. The only difference in the treatmentof
these two series has been the addition of potassium iodide to the therapeutic
regime in Series 11. Three other possible differences are examined as follows:
(1) Comparison of total average dosaae -per patient of cyclophosphamide.
In Series I this was 3.4 g. and in Series 11, 3-1 g.
(2) Comparison of number of courses of treatment.
Series I Series H
No. of courses 1 2 3 4 1 2 3 4
No. ofpationtr, 13 9 0 2 9 8 3 4
One course only because died soon 4 - - - 4 - - -
No. ofpatients wbo died 10 6 0 2 3 2 1 2
No. ofpatients alive over 50 week8 3 3 0 0 4 1 0 2
(3) Comparison offollow-up.
Series I Series II
Patients dying too soon for follow-up 2 3
Patients returning voluntarily 4 6
Patients visited at home 13 12
Patients not seen again before death 5 3
Experimental work has been carried out to try and elucidate a reason for the
apparent potentiating effect of potassium iodide (Connors, T. A., personal com-
munication). This has so far yielded negative results. No firm conclusion can
therefore bereached as to thevalidity oftheassumptionthatpotassiumiodide may potentiate cyclophosphamide.
CONCLUSION
For some reason which has so far eluded us, potassium iodide appears to have
produced improved survival rates in the treatment of Burkitt's lymphoma patients with cyclophosphamide. If the reason for this result could be found
doubtless a more effective potentiating agent could be suggested. Improved results have also been found in treating other malignancies, and in particular it
has beenfoundthatcomparative survival curves ofpatientswithhepatomatreated
in the same wav show a slight average prolongation oflife. More time, however, is needed to assess these results.
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